Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 321 - 340 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
1Q12 Results; Status Quo Before Anticipated July AMR101 Approval
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Q1:2012 Recap; Approaching July PDUFA for AMR101; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Competitive Overhang Diminished as AMR101 Still Appears Best-in-Class; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Assuming Coverage with OUTPERFORM and $19 Fair Value
Provider: WEDBUSH SECURITIES INC.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 25
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Allowance for ''598, Patent Clouds Starting to Clear
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
2011 Results; Navigating IP "Setbacks" & Straight Course to July PDUFA
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Uneventful Quarterly Report Overshadowed by Non-Final Patent Rejection; Reaction Overdone; Raising FV to $19
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
AMR101 REDUCE-IT Outcomes Study Begins Patient Dosing on Schedule; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Q3:2011 Review: Patent Application Red Herring Presents Buying Opportunity; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of October 2.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Files for Re-Examination of AMR101 Patent Application; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: NASH D